Related Experiment Videos
Pharmacological profile of MDL 26,024GO: a novel antiasthmatic agent
L Baugh1, W Abraham, E Matthews
1Merrel Dow Research Institute, Cincinnati, OH.
Abstract:
MDL 26,024GO was shown to be an orally absorbed mediator release inhibitor in the rat PCA and PPA tests. In addition, the compound was shown to both elicit and inhibit elicitation of the Bezold-Jarisch reflex in the dog. MDL 26,024GO also significantly reduced Ascaris-induced changes in pulmonary mechanics in cynomolgus monkeys. The compound inhibited both early and late phase antigen induced-changes in Ascaris-sensitive sheep, as well as the increased airway hyperreactivity which normally follows antigen challenge. These results suggest the compound may have therapeutic potential in the treatment of asthma.
Insights
MDL 26,024GO, an orally absorbed mediator release inhibitor, demonstrated potential for treating asthma by reducing allergic responses in animal models. The compound effectively inhibited antigen-induced airway changes and hyperreactivity.
Area of Science:
- Pharmacology
- Immunology
- Respiratory Medicine
Background:
- Asthma is a chronic respiratory disease characterized by airway inflammation and hyperresponsiveness.
- Current treatments aim to manage symptoms and reduce exacerbations, but novel therapeutic targets are needed.
Purpose of the Study:
- To evaluate the efficacy of MDL 26,024GO as a potential therapeutic agent for asthma.
- To assess the compound's effects on mediator release and allergic responses in preclinical models.
Main Methods:
- Administered MDL 26,024GO orally in rat passive cutaneous anaphylaxis (PCA) and passive paw anaphylaxis (PPA) tests.
- Investigated the Bezold-Jarisch reflex in dogs.
- Assessed effects on Ascaris-induced pulmonary mechanics in cynomolgus monkeys.
- Evaluated antigen-induced early and late phase responses and airway hyperreactivity in Ascaris-sensitive sheep.
Main Results:
- MDL 26,024GO acted as an orally absorbed mediator release inhibitor in rat models.
- The compound modulated the Bezold-Jarisch reflex in dogs.
- Significant reduction in Ascaris-induced pulmonary changes was observed in monkeys.
- Inhibition of both early and late phase allergic responses and subsequent airway hyperreactivity in sheep.
Conclusions:
- MDL 26,024GO exhibits significant anti-inflammatory and anti-allergic properties in various animal models.
- The compound's ability to inhibit mediator release and allergic responses suggests therapeutic potential for asthma treatment.